Endeavour Silver Q3 2026 net earnings swing to USD 26.4 million profit
Bitget2026/11/09 22:09- Endeavour Silver swung to Q3 2026 net earnings of USD 26.4 million from a year-earlier loss of USD 42.01 million.
- Revenue rose to USD 184.5 million, supported by higher metal prices.
- Silver production climbed 19% year-over-year to 2,096,545 ounces, while gold output increased 39% to 10,126 ounces.
- Revised 2026 production guidance targets 7,800,000–8,100,000 ounces of silver and 42,000–43,500 ounces of gold.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
